למזיד Israël - hébreu - Ministry of Health

למזיד

kamada ltd, israel - velmanase alfa - אבקה להכנת תמיסה לאינפוזיה - velmanase alfa 10 mg/vial - velmanase alfa

סביבו Israël - hébreu - Ministry of Health

סביבו

novartis pharma services ag - telbivudine 600 mg - film coated tablets - telbivudine - treatment of chronic hepatitis b in patients with evidence of viral replication and active liver inflammation in adults over 16 years of age.the following points should be considered when initiating therapy with sebivo:- for hbeag - positive patients, sebivo treatment should only be initiated in patients with baseline hbv dna < 9log 10 copies/ml and baseline alt>or= 2x uln.- for hbeag - negative patients, sebivo treatment should only be initiated in patients with baseline hbv dna < 7log 10 copies/ml.

אוויפלרה Israël - hébreu - Ministry of Health

אוויפלרה

j-c health care ltd - emtricitabine; rilpivirine as hydrochloride; tenofovir disoproxil as fumarate - טבליות מצופות פילם - tenofovir disoproxil as fumarate 245 mg; rilpivirine as hydrochloride 25 mg; emtricitabine 200 mg - rilpivirine - rilpivirine - eviplera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) is indicated for use as a complete regimen for the treatment of hiv-1 infection in antiretroviral treatment-naive adults. this indication is based on week 48 safety and efficacy analyses from 2 randomized, double-blind, active controlled, phase 3 trials in treatment-naive subjects comparing rilpivirine to efavirenz . the following points should be considered when initiating therapy with eviplera: -more rilpivirine-treated subjects with hiv-1 rna greater than 100,000 copies/ml at the start of therapy experienced virologic failure compared to subjects with hiv-1 rna less than 100,000 copies/ml at the start of therapy. -the observed virologic failure rate in rilpivirine-treated subjects conferred a higher rate of overall treatment resistance and cross-resistance to the nnrti class compared to efavirenz . -more subjects treated with rilpivirine developed lamivudine/emtricitabine associated resistance compared to efavirenz. -eviplera is not recomme

אוויפלרה Israël - hébreu - Ministry of Health

אוויפלרה

j-c health care ltd - emtricitabine; rilpivirine as hydrochloride; tenofovir disoproxil as fumarate - טבליות מצופות פילם - tenofovir disoproxil as fumarate 245 mg; rilpivirine as hydrochloride 25 mg; emtricitabine 200 mg - rilpivirine - rilpivirine - eviplera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) is indicated for use as a complete regimen for the treatment of hiv-1 infection in antiretroviral treatment-naive adults. this indication is based on week 48 safety and efficacy analyses from 2 randomized, double-blind, active controlled, phase 3 trials in treatment-naive subjects comparing rilpivirine to efavirenz . the following points should be considered when initiating therapy with eviplera: -more rilpivirine-treated subjects with hiv-1 rna greater than 100,000 copies/ml at the start of therapy experienced virologic failure compared to subjects with hiv-1 rna less than 100,000 copies/ml at the start of therapy. -the observed virologic failure rate in rilpivirine-treated subjects conferred a higher rate of overall treatment resistance and cross-resistance to the nnrti class compared to efavirenz . -more subjects treated with rilpivirine developed lamivudine/emtricitabine associated resistance compared to efavirenz. -eviplera is not recomme

אודפסיי Israël - hébreu - Ministry of Health

אודפסיי

j-c health care ltd - emtricitabine; rilpivirine as hydrochloride; tenofovir alafenamide as fumarate - טבליות מצופות פילם - tenofovir alafenamide as fumarate 25 mg; emtricitabine 200 mg; rilpivirine as hydrochloride 25 mg - rilpivirine

אודפסיי Israël - hébreu - Ministry of Health

אודפסיי

j-c health care ltd - emtricitabine; rilpivirine as hydrochloride; tenofovir alafenamide as fumarate - טבליות מצופות פילם - tenofovir alafenamide as fumarate 25 mg; emtricitabine 200 mg; rilpivirine as hydrochloride 25 mg - rilpivirine

ווקבריה זריקה Israël - hébreu - Ministry of Health

ווקבריה זריקה

glaxo smith kline (israel) ltd - cabotegravir - cabotegravir 200 mg / 1 ml

ווקבריה טבליות Israël - hébreu - Ministry of Health

ווקבריה טבליות

glaxo smith kline (israel) ltd - cabotegravir as sodium - טבליות מצופות פילם - cabotegravir as sodium 30 mg

אבילק סירופ Israël - hébreu - Ministry of Health

אבילק סירופ

padagis israel pharmaceuticals ltd, israel - lactulose - סירופ - lactulose 66.7 g / 100 ml - lactulose - lactulose - constipation. acute and chronic hepatic encephalopathy.

טייקרב Israël - hébreu - Ministry of Health

טייקרב

novartis israel ltd - lapatinib as ditosylate monohydrate - טבליות מצופות פילם - lapatinib as ditosylate monohydrate 250 mg - protein kinase inhibitors - tykerb is indicated for the treatment of adult patients with breast cancer, whose tumours overexpress her2 (erbb2);• in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting (see section 5.1).• tykerb is indicated in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer that overexpresses the her2 receptor for whom hormonal therapy is indicated. tykerb in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer.